Amneal Pharmaceuticals has announced positive topline results from the phase 3 RISE-PD trial evaluating a novel formulation of carbidopa/levodopa for patients with Parkinson’s disease (PD) who have motor fluctuations. “IPX-203 was developed with an innovative formulation that contains immediate-release and extended-release granules, and mucoadhesive polymers, to provide rapid absorption and maximize levodopa absorption,” the company